Ensol Biosciences, Inc.

As of December 31, 2025, Ensol Biosciences, Inc. carries a market capitalization of 175.59B, placing it among publicly traded companies globally. Its enterprise value stands at 156.99B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Ensol Biosciences, Inc. has 13.37M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 6,642.65, and the price-to-book ratio stands at 12.94.

These figures are as of December 31, 2025. The EV/Sales ratio of 6,265.75 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 156.99B versus a market cap of 175.59B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Ensol Biosciences, Inc. maintains a current ratio of 1.70, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 61.25, indicating elevated leverage, while an interest coverage ratio of -5.99 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -27.21, reflecting losses generated across the asset base. The company generates approximately 894,857.14 in revenue per employee across its workforce of 28.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.20 indicates how many times Ensol Biosciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, Ensol Biosciences, Inc.'s stock has declined approximately 47.09% over the past 52 weeks. The 50-day moving average sits at 9,952.00, while the 200-day moving average is 12,356.70.

Over the twelve months ended December 31, 2025, Ensol Biosciences, Inc. generated 25.06M in revenue and converted that into -5.34B in net income, yielding earnings per share of -420.93. EBITDA reached -6.74B, while operating income came in at -7.19B.

As of December 31, 2025, Ensol Biosciences, Inc. holds 26.90B in cash and equivalents against 8.31B in total debt, resulting in a net debt position of 7.07B. Total book value stands at 13.57B, with working capital of 11.44B providing operational flexibility.

Ensol Biosciences, Inc. produced -6.67B in operating cash flow over the twelve months ended December 31, 2025. After subtracting -30.87M in capital expenditures, free cash flow totaled -6.70B - equivalent to -528.79 per share.

Over the twelve months ended December 31, 2025, Ensol Biosciences, Inc. posted a gross margin of 83.88, reflecting its pricing power and cost economics. The operating margin of -28,695.26 and net profit margin of -21,295.21 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -4.03: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -17.94, meaning Ensol Biosciences, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2025, Ensol Biosciences, Inc. has an Altman Z-Score of 1.22, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.